tetano
Editor, Senior Moderator
Vaccine X. 2019 Jun 19;2:100031. doi: 10.1016/j.jvacx.2019.100031. eCollection 2019 Aug 9.
[h=1]Evaluation of A(H1N1)pdm09 LAIV vaccine candidates stability and replication efficiency in primary human nasal epithelial cells.[/h] Shcherbik S[SUP]1[/SUP], Pearce N[SUP]1,[/SUP][SUP]2[/SUP], Carney P[SUP]1[/SUP], Bazhenova E[SUP]3[/SUP], Larionova N[SUP]3[/SUP], Kiseleva I[SUP]3[/SUP], Rudenko L[SUP]3[/SUP], Kumar A[SUP]1,[/SUP][SUP]2[/SUP], Goldsmith CS[SUP]4[/SUP], Dugan V[SUP]1[/SUP], Stevens J[SUP]1[/SUP], Wentworth DE[SUP]1[/SUP], Bousse T[SUP]1[/SUP].
[h=3]Author information[/h] 1 Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, United States. 2 Battelle, Atlanta, GA 30329, United States. 3 Institute of Experimental Medicine, Department of Virology, St. Petersburg, Russia. 4 Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, United States.
[h=3]Abstract[/h] The recent reduction of live attenuated influenza vaccine (LAIV) effectiveness in multivalent formulations was particularly associated with the A(H1N1)pdm09 component. In the 2017 the WHO vaccine composition committee changed its recommendations for the A(H1N1)pdm09 component to include an A/Michigan/45/2015-like virus. We evaluated effectiveness and quality of newly developed and previous A(H1N1)pdm09 LAIV reassortants through assessment of their thermal and pH stability, receptor binding specificity and replication fitness in primary human airway epithelial cells of nasal origin (hAECN). Our analysis showed that LAIV expressed hemagglutinin (HA) and neuraminidase (NA) from an A/Michigan/45/2015-like strain A/New York/61/2015 (A/New York/61/2015-CDC-LV16A, NY-LV16A), exhibit higher thermal and pH stability compared to the previous vaccine candidates expressing HA and NA from A/California/07/2009 and A/Bolivia/559/2013 (A17/Cal09 and A17/Bol13). Reassortants A/South Africa/3626/2013-CDC-LV14A (SA-LV14A) and NY-LV16A showed preferential binding to α2,6 sialic acid (SA) receptors and replicated at higher titers and more extensively in hAECN compared to A17/Cal09 and A17/Bol13, which had an α2,3 SA receptor binding preference. Our data analysis supports selection of A/New York/61/2015-CDC-LV16A for LAIV formulation and the introduction of new assays for LAIV characterization.
[h=4]KEYWORDS:[/h] A(H1N1)pdm09 LAIV; Glycan; Replication; Stability; hAECN
PMID: 31384746 PMCID: PMC6668239 DOI: 10.1016/j.jvacx.2019.100031
Free PMC Article
[h=1]Evaluation of A(H1N1)pdm09 LAIV vaccine candidates stability and replication efficiency in primary human nasal epithelial cells.[/h] Shcherbik S[SUP]1[/SUP], Pearce N[SUP]1,[/SUP][SUP]2[/SUP], Carney P[SUP]1[/SUP], Bazhenova E[SUP]3[/SUP], Larionova N[SUP]3[/SUP], Kiseleva I[SUP]3[/SUP], Rudenko L[SUP]3[/SUP], Kumar A[SUP]1,[/SUP][SUP]2[/SUP], Goldsmith CS[SUP]4[/SUP], Dugan V[SUP]1[/SUP], Stevens J[SUP]1[/SUP], Wentworth DE[SUP]1[/SUP], Bousse T[SUP]1[/SUP].
[h=3]Author information[/h] 1 Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, United States. 2 Battelle, Atlanta, GA 30329, United States. 3 Institute of Experimental Medicine, Department of Virology, St. Petersburg, Russia. 4 Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, United States.
[h=3]Abstract[/h] The recent reduction of live attenuated influenza vaccine (LAIV) effectiveness in multivalent formulations was particularly associated with the A(H1N1)pdm09 component. In the 2017 the WHO vaccine composition committee changed its recommendations for the A(H1N1)pdm09 component to include an A/Michigan/45/2015-like virus. We evaluated effectiveness and quality of newly developed and previous A(H1N1)pdm09 LAIV reassortants through assessment of their thermal and pH stability, receptor binding specificity and replication fitness in primary human airway epithelial cells of nasal origin (hAECN). Our analysis showed that LAIV expressed hemagglutinin (HA) and neuraminidase (NA) from an A/Michigan/45/2015-like strain A/New York/61/2015 (A/New York/61/2015-CDC-LV16A, NY-LV16A), exhibit higher thermal and pH stability compared to the previous vaccine candidates expressing HA and NA from A/California/07/2009 and A/Bolivia/559/2013 (A17/Cal09 and A17/Bol13). Reassortants A/South Africa/3626/2013-CDC-LV14A (SA-LV14A) and NY-LV16A showed preferential binding to α2,6 sialic acid (SA) receptors and replicated at higher titers and more extensively in hAECN compared to A17/Cal09 and A17/Bol13, which had an α2,3 SA receptor binding preference. Our data analysis supports selection of A/New York/61/2015-CDC-LV16A for LAIV formulation and the introduction of new assays for LAIV characterization.
[h=4]KEYWORDS:[/h] A(H1N1)pdm09 LAIV; Glycan; Replication; Stability; hAECN
PMID: 31384746 PMCID: PMC6668239 DOI: 10.1016/j.jvacx.2019.100031
Free PMC Article